Johnson & Johnson (NYSE:JNJ) Stock to Pay Quarterly Dividend of $1.34

Johnson & Johnson (NYSE:JNJ) declared a quarterly dividend on Tuesday, October 13th. Investors of record on Tuesday, November 24th will be given a dividend of $1.34 per share on Tuesday, December 8th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, November 24th.

Johnson & Johnson has raised its dividend payment by an average of 0.1% annually over the last three years and has increased its dividend every year for the last 64 years. Johnson & Johnson has a payout ratio of 48.3% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Johnson & Johnson to earn $12.33 per share next year, which means the company should continue to be able to cover its $5.36 annual dividend with an expected future payout ratio of 43.5%.

Johnson & Johnson Trading Down 5.6%

Shares of NYSE:JNJ traded down $14.83 during mid-day trading on Tuesday, reaching $248.90. 16,613,205 shares of the company were exchanged, compared to its average volume of 7,994,569. Johnson & Johnson has a 1 year low of $184.66 and a 1 year high of $281.07. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The firm’s 50-day simple moving average is $266.01 and its 200 day simple moving average is $249.31. The firm has a market cap of $599.83 billion, a price-to-earnings ratio of 28.84, a P/E/G ratio of 2.65 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. The company had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%. The firm’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.80 earnings per share. Equities research analysts forecast that Johnson & Johnson will post 11.18 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. The Goldman Sachs Group restated a “buy” rating and set a $282.00 price target on shares of Johnson & Johnson in a research report on Thursday, July 16th. Guggenheim reiterated a “buy” rating and issued a $287.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 7th. Argus set a $300.00 target price on Johnson & Johnson in a research note on Wednesday, July 29th. Johnson Rice restated a “buy” rating on shares of Johnson & Johnson in a report on Monday, August 3rd. Finally, Freedom Capital upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $276.22.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.